natgillin/translations-raw huggingface dataset:
The European Commission granted a marketing authorisation valid throughout the European Union for Zenapax to Roche Registration Limited on 26 February 1999. 
Evropska komisija je dovoljenje za promet z zdravilom Zenapax, veljavno po vsej Evropski uniji, odobrila družbi Roche Registration Limited dne 26. februarja 1999.
The recommended dose for adults and children is 1 mg per kilogram body weight, diluted in 50 ml sterile saline solution and given over 15 minutes. 
Priporočeni odmerek za odrasle in otroke je 1 mg na kilogram telesne mase, ki se razredči v 50 ml sterilne fiziološke raztopine ter daje v obdobju 15 minut.
It contains the active substance daclizumab (5 mg/ml). 
Vsebuje zdravilno učinkovino daclizumab (5 mg/ml).
If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Če potrebujete več informacij o vašem zdravstvenem stanju ali zdravljenju, preberite Navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali s farmacevtom.
Other information about Zenapax: 
Druge informacije o zdravilu Zenapax:
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on certain cells in the body. 
Monoklonsko protitelo je protitelo (vrsta beljakovine), ki prepoznava in se veže na specifično strukturo (imenovano antigen), ki se nahaja na določenih celicah v telesu.
The most common side effects (seen in more than 1 patient in 10) were insomnia (difficulty sleeping), tremor (shaking), headache, hypertension (high blood pressure), dyspnoea (difficulty breathing), constipation, diarrhoea, vomiting, nausea (feeling sick), dyspepsia (heartburn), musculoskeletal pain (pain in the muscles and joints), oedema (swelling), impaired healing and post-traumatic pain (pain after surgery). 
Najpogostejši neželeni učinki (opaženi pri več kot 1 bolniku od 10) so bili nespečnost (težave pri spanju), tremor (tresenje), glavobol, hipertenzija (visok krvni tlak), dispneja (oteženo dihanje), zaprtje, driska, bruhanje, slabost, dispepsija (zgaga), mišično-skeletne bolečine (bolečine v mišicah in sklepih), edem (otekanje), slabše celjenje in posttravmatske bolečine (bolečine po kirurškem posegu).
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ZENAPAX EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) ZENAPAX Povzetek EPAR za javnost
The main measure of effectiveness was the proportion of patients who experienced rejection of the transplanted kidney in the first six months after the transplant. 
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih je prišlo do zavrnitve presajene ledvice v prvih šestih mesecih po presaditvi.
The subsequent doses should be given every 14 days for a total of five doses. 
Nadaljnji odmerki se dajejo vsakih 14 dni.
Zenapax should only be prescribed and given by doctors who have experience in the use of immunosuppressive treatment following organ transplant. 
Zdravilo Zenapax smejo predpisati in uporabljati le zdravniki, ki imajo izkušnje z imunosupresivnim zdravljenjem po presaditvi organa.
Zenapax has been studied in two main studies involving a total of 535 adults undergoing kidney transplant. 
Zdravilo Zenapax so preučili v dveh glavnih študijah, v kateri je bilo vključenih 535 odraslih bolnikov s presaditvijo ledvice.
A further study looked at rejection rates in 60 children aged between five and 18 years who were undergoing a kidney transplant. 
V dodatni študiji so ugotavljali stopnje zavrnitve pri 60 otrocih, starih od 5 do 18 let, katerim so presadili ledvico.
Zenapax should not be used in people who may be hypersensitive (allergic) to daclizumab or any of the other ingredients. 
Zdravila Zenapax se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) daclizumab ali katerokoli drugo sestavino zdravila.
The Committee recommended that Zenapax be given marketing authorisation. 
Odbor je priporočil odobritev dovoljenja za promet z zdravilom Zenapax.
What benefit has Zenapax shown during the studies? 
Kakšne koristi je zdravilo Zenapax izkazalo med študijami?
By binding to and blocking the receptor, daclizumab prevents interleukin-2 activating the T-lymphocytes, reducing the chance that the transplanted kidney will be rejected. 
Ko se daclizumab veže na receptor in ga blokira, prepreči, da bi interlevkin-2 aktiviral limfocite T, s tem pa zmanjša možnost zavrnitve presajene ledvice.
In this study, Zenapax was added to the children's existing immunosuppressive medicines. 
V tej študiji so zdravilo Zenapax dodajali obstoječim imunosupresivnim zdravilom.
It is used together with other immunosuppressive (anti-rejection) medicines including ciclosporin and corticosteroids. 
Uporablja se skupaj z drugimi imunosupresivnimi učinkovinami (učinkovinami za preprečevanje zavrnitve), vključno s ciklosporinom in kortikosteroidi.
azathioprine. 
prednizon in azatioprin.
The active substance in Zenapax, daclizumab, is a monoclonal antibody. 
Zdravilna učinkovina zdravila Zenapax je daclizumab, ki je monoklonsko protitelo.
In the first study, the patients were receiving ciclosporin and prednisone (a corticosteroid), and in the second study, they were receiving ciclosporin, prednisone and 
V prvi študiji so bolniki prejemali ciklosporin in prednizon (kortikosteroid), v drugi študiji pa so prejemali ciklosporin,
In the study of children, five (8%) experienced rejection in the first six months after the transplant. 
V študiji pri otrocih je prišlo do zavrnitve v prvih šestih mesecih po presaditvi pri 5 (8 %) otrocih.
The Committee for Medicinal Products for Human Use (CHMP) decided that Zenapax's benefits are greater than its risks for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation, used concomitantly with an immunosuppressive regimen, including ciclosporin and corticosteroids in patients who are not highly immunised. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristni učinki zdravila Zenapax pri preprečevanju akutne zavrnitve organa pri de novo alogeni ledvični transplantaciji pri bolnikih, ki niso visoko senzibilizirani, ob sočasnem režimu imunosupresivnih zdravil, vključno s ciklosporinom in kortikosteroidi, večji od z njim povezanih tveganj.
What is the risk associated with Zenapax? 
Kakšna tveganja so povezana z zdravilom Zenapax?
For the full list of side effects reported with Zenapax, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zenapax, glejte Navodilo za uporabo.
Zenapax is a concentrate to be made up into a solution for infusion (drip into a vein). 
Zdravilo Zenapax je koncentrat, ki se pripravi v raztopino za infundiranje (dajanje tekočine v veno).
In the first study, 28 (22%) of the 126 adults adding Zenapax to ciclosporin and prednisone experienced rejection, compared with 47 (35%) of the 134 adding placebo. 
V prvi študiji je do zavrnitve prišlo pri 28 (22 %) od 126 odraslih bolnikov, pri katerih so zdravilo Zenapax dodajali ciklosporinu in prednizonu, in pri 47 (35 %) od 134 odraslih bolnikov, pri katerih so ciklosporinu in prednizonu dodajali placebo.
Zenapax is used to prevent the body from rejecting a kidney soon after a transplant. 
Zdravilo Zenapax se uporablja za preprečevanje zavrnitve ledvice po presaditvi.
In the second study, 39 (28%) of the 141 adults adding Zenapax to ciclosporin, prednisone and azathioprine experienced rejection of the kidney, compared with 63 (47%) of the 134 adding placebo. 
V drugi študiji je do zavrnitve ledvice prišlo pri 39 (28 %) od 141 odraslih bolnikov, pri katerih so zdravilo Zenapax dodajali ciklosporinu, prednizonu in azatioprinu, in pri 63 (47 %) od 134 odraslih bolnikov, pri katerih so ciklosporinu, prednizonu in azatioprinu dodajali placebo.
The full EPAR for Zenapax can be found here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zenapax je na voljo tukaj.
Why has Zenapax been approved? 
Zakaj je bilo zdravilo Zenapax odobreno?
Both studies compared the effects of adding Zenapax or placebo (a dummy treatment) to other immunosuppressive medicines. 
V študijah so primerjali učinke uporabe zdravila Zenapax ali placeba (zdravila brez zdravilne učinkovine) v kombinaciji z drugimi imunosupresivnimi zdravili.
Zenapax must not be used in women who are breast feeding. 
Zdravila Zenapax ne smejo uporabljati doječe matere.
Zenapax was more effective than placebo in reducing the rate of rejection when added to immunosuppressive therapy. 
Dodajanje zdravila Zenapax imunosupresivnim zdravilom je bilo glede stopnje zavrnitve učinkovitejše od dodajanja placeba.
Daclizumab has been designed to bind to the receptor for interleukin-2 on the surface of white blood cells called T-lymphocytes. 
Daclizumab je zasnovan tako, da se veže na receptor za interlevkin-2, ki se nahaja na površini belih krvničk, ki jim pravimo limfociti T. Te celice sodelujejo pri prepoznavanju „tujih“ celic in zavračanju presajenih organov.
In studies, side effects were seen at similar rates in patients taking Zenapax and those taking placebo, when given in combination with immunosuppressive medicines. 
V študijah so ugotovili, da se neželeni učinki pri bolnikih, ki so jemali zdravilo Zenapax v kombinaciji z imunosupresivnimi zdravili, pojavljajo s podobno pogostostjo kot pri bolnikih, katerim so dodajali placebo.
How does Zenapax work? 
Kako zdravilo Zenapax deluje?
How has Zenapax been studied? 
Kako je bilo zdravilo Zenapax raziskano?
What is Zenapax? 
Kaj je zdravilo Zenapax?
What is Zenapax used for? 
Za kaj se zdravilo Zenapax uporablja?
How is Zenapax used? 
Kako se zdravilo Zenapax uporablja?
Produced from the plasma of human donors. 
Proizvedeno iz plazme človeških darovalcev.
This must be carried out in hospital or under the careful supervision of a doctor. 
To mora biti izvedeno v bolnišnici ali pod skrbnim nadzorom zdravnika.
The other (serious and non-serious) adverse reactions were received by spontaneous reporting. 
Podatki o drugih (resnih in ne-resnih) neželenih učinkih so bili prejeti s spontanim poročanjem.
Frequencies have been evaluated according to the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data) 
Pogostost je bila ocenjena skladno z naslednjim dogovorom: zelo pogosti (≥ 1/10); pogosti (od ≥ 1/100 do < 1/10); občasni (od ≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
You should discuss the possible side effects with your doctor in order to know how to recognise them and what to do if they occur. 
O možnih neželenih učinkih se pogovorite s svojim zdravnikom, da boste vedeli, kako jih prepoznati in kaj storiti, če se pojavijo.
Previously untreated patients 
Predhodno nezdravljeni bolniki
The required dose is determined using the following formula: 
Potrebno odmerjanje določimo z uporabo naslednje formule:
It allows continued monitoring of the benefit/risk balance of the medicinal product. 
Omogoča nadaljevanje spremljanja razmerja med koristmi in tveganji zdravila.
If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. 
Če se taki inhibitorji pojavijo, se bo to pokazalo kot nezadosten klinični odziv.
This will show itself as an increased tendency to bleed. 
To se bo pokazalo kot povečana nagnjenost h krvavitvam.
Do not use this medicine after the expiry date which is stated on the label and carton. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na oznaki in škatli.
In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary. 
V nekaterih primerih, posebno pri mlajših bolnikih, bodo morda potrebni krajši intervali med odmerki ali višji odmerki.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. 
Poročanje o domnevnih neželenih učinkih po pridobitvi dovoljenja za promet z zdravilom je pomembno.
Thrombin then converts fibrinogen into fibrin and a clot is formed. 
Trombin nato pretvori fibrinogen v fibrin in oblikuje se strdek.
Chemical and physical in-use stability has been demonstrated for 3 hours at a temperature of 21°C. 
Po pripravi: Kemijska in fizikalna stabilnost med uporabo je dokazana za 3 ure pri temperaturi 21 °C.
For safety information with respect to transmissible agents, see 4.4. 
Za podatke o varnosti glede prenosljivih agensov glejte poglavje 4.4.
OTHER SPECIAL WARNING(S), IF NECESSARY Do not use if the solution is not totally clear or if the powder is not totally reconstituted. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Ne uporabite, če raztopina ni popolnoma bistra ali če prašek ni popolnoma raztopljen.
If you have to undergo surgery or have a tooth extracted, inform your doctor or dentist that you have factor IX deficiency. 
Če vam morajo opraviti operacijo ali izruvati zob, obvestite vašega zdravnika ali zobozdravnika, da imate pomanjkanje faktorja IX.
The clinical relevance of antibodies to mouse protein, if these do indeed arise, is not known. 
Klinični pomen protiteles proti mišjim beljakovinam, če se ta res pojavijo, ni znan.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines, even those not prescribed. 
Obvestite zdravnika, farmacevta ali medicinsko sestro, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi takšna, ki se izdajajo brez recepta.
Renewal of authorisation: 03 July 2006 
Datum pridobitve dovoljenja za promet: 3. julij 2001 Podaljšanje dovoljenja za promet: 3. julij 2006
They will then ensure that factor IX is administered to you, should this prove necessary. 
Oni bodo potem poskrbeli, da boste prejeli faktor IX, če bo to potrebno.
The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. 
Imetnik dovoljenja za promet z zdravilom mora posredovati periodično posodobljena poročila o varnosti skladno z zahtevami, opredeljenimi na seznamu referenčnih datumov EU (seznamom EURD), ki je naveden v členu 107c(7) Direktive 2001/83/ES in objavljen na spletnem portalu Evropske agencije za zdravila.
Reporting of side effects 
Poročanje o stranskih učinkih
The use of high purity factor IX is rarely associated with such adverse reactions. 
Uporabo visoko prečiščenega faktorja IX le redko povezujejo s takimi neželenimi učinki.
If you have the impression that the effect of Nonafact is too strong or too weak, talk to your doctor. 
Če menite, da je učinek zdravila Nonafact premočan ali prešibak, se posvetujte s svojim zdravnikom.
These are conditions that increase your risk of developing internal blood clots. 
To so stanja, ki povečujejo vaše tveganje za razvoj krvnih strdkov.
Disinfect the surface of the stoppers of both vials with a gauze soaked in 70 % alcohol. 
Razkužite površino zapork obeh vial z gazo, prepojeno s 70 % alkoholom.
If you are allergic to human coagulation factor IX or to any of the ingredients of this medicine (listed in section 6). 
Če ste alergični na humani koagulacijski faktor IX ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
BATCH NUMBER Lot: {number} 
ŠTEVILKA SERIJE Lot: {številka}
This also applies to newborn babies and patients with an increased risk of thrombosis or “DIC” (disseminated intravascular coagulation) a disease in which the blood coagulation system is disturbed. 
To velja tudi za novorojenčke in bolnike s povečanim tveganjem za trombozo ali »DIK« (diseminirano intravaskularno koagulacijo),bolezen pri kateri je moteno delovanje sistema strjevanja krvi.
Neutralising antibodies (Inhibitors) 
Nevtralizirajoča protitelesa (inhibitorji)
Individual patients may vary in their response to factor IX, demonstrating different half-lives and recoveries. 
Posamezni bolniki se lahko v svojem odzivu na faktor IX razlikujejo ter izkazujejo različne razpolovne čase in okrevanje.
Paediatric population The listed warnings and precautions apply both to adults and children. 
Pediatrična populacija Navedena opozorila in previdnostni ukrepi veljajo za odrasle in otroke.
DD month YYYY 
DD mesec LLLL
Once dissolved, the product should be used immediately (at least within 3 hours). 
Ko je zdravilo enkrat raztopljeno, ga moramo takoj uporabiti (najpozneje v 3 urah).
Factor IX in this product therefore behaves like endogenous factor IX. 
Faktor IX v tem zdravilu se torej obnaša kot endogeni faktor IX.
Your doctor will check your blood regularly for the presence of these antibodies. 
Vaš zdravnik vam bo redno pregledoval kri za morebitno navzočnost teh protiteles.
ANNEX II A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OF THE MARKETING AUTHORISATION C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PRILOGA II A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE B. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
In such cases, it is recommended that a specialised haemophilia centre be contacted. 
V takih primerih priporočamo posvetovanje s specializiranim centrom za hemofilijo.
Your doctor will check your blood regularly for the presence of these antibodies, especially if you experienced a severe allergic reaction with the previous use of a factor IX product. 
Vaš zdravnik bo redno pregledoval vašo kri zaradi možne prisotnosti teh protiteles, še posebej, če ste doživeli hudo alergijsko reakcijo ob uporabi zdravila s faktorjem IX v preteklosti.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V *. 
Zdravstveno osebje mora o kakršnih koli domnevnih neželenih učinkih poročati prek nacionalnega sistema za poročanje, ki je naveden v Prilogi V.*
Factor IX is a normal constituent of human blood. 
Faktor IX je normalna sestavina človeške krvi.
If you are allergic to mouse protein or have had any reactions to mouse protein. 
Če ste alergični na mišje beljakovine ali ste imeli kakršno koli reakcijo na mišje beljakovine.
for intravenous use 
za intravensko uporabo
Viral safety 
Virusna varnost
Swirl the vial gently to completely dissolve the powder within 5 minutes. 
Nežno vrtite vialo, da popolnoma raztopite prašek v 5 minutah.
Therefore, patients experiencing allergic reactions should be evaluated for the presence of an inhibitor. 
Zato moramo pri bolnikih z alergijskimi reakcijami preveriti navzočnost inhibitorja.
Factor IX is a single chain glycoprotein with a molecular mass of about 68,000 Dalton. 
Faktor IX je enoverižni glikoprotein z molekulsko maso približno 68.000 Daltonov.
Treatment should be under the supervision of a physician experienced in the treatment of haemophilia. 
Zdravljenje mora potekati pod nadzorom zdravnika, izkušenega v zdravljenju hemofilije.
Minor surgery including tooth extraction 
Manjši kirurški posegi, vključno z izruvanjem zoba
The product should be used immediately. 
Zdravilo morate uporabiti takoj.
Nonafact has a half-life of approximately 19 (17 - 21) hours. 
Zdravilo Nonafact ima razpolovni čas približno 19 (od 17 do 21) ur.
The exact dose will depend on the seriousness of the clinical situation, your body weight and the amount of factor IX in your blood. 
Točni odmerek bo odvisen od resnosti kliničnega stanja, vaše telesne mase in količine faktorja IX v vaši krvi.
Activated factor IX, in combination with activated factor VIII, activates factor X. Activated factor X converts prothrombin into thrombin. 
Aktivirani faktor IX v kombinaciji z aktiviranim faktorjem VIII aktivira faktor X. Aktivirani faktor X pretvori protrombin v trombin.
MM/YYYY 
MM/LLLL
From a microbiological point of view the product, once dissolved, should be used immediately, but no longer than 3 hours after reconstitution. 
Z mikrobiološkega vidika je treba zdravilo, ko ga enkrat raztopimo, nemudoma uporabiti, toda ne kasneje kot 3 ure po rekonstituciji.
(pre- and postoperative) 
(pred in po operaciji)
1066 CX Amsterdam The Netherlands 
1066 CX Amsterdam Nizozemska
You should tell your doctor if you know that you have a risk of thrombosis or you have had thromboembolic complications in the past, if you suffer from liver disease, cardiovascular disease, or if a surgery is planned. 
Zdravniku morate sporočiti, če veste, da pri vas obstaja tveganje tromboze ali ste v preteklosti imeli trombembolične zaplete, če imate obolenje jeter, srčno-žilno bolezen ali načrtovan kirurški poseg.
For instructions on reconstitution of the medicinal product before administration, see section 6. 
Za navodila glede rekonstitucije zdravila pred dajanjem glejte poglavje 6.
The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case. 
Količino za dajanje in pogostost dajanja moramo vedno določiti glede na klinično učinkovitost pri posameznem bolniku.
This leaflet was last approved 
Navodilo je bilo nazadnje revidirano dne
20-40 Repeat infusion every 24 hours. 
20-40 Ponovite infuzijo vsakih 24 ur.
Dissolving the powder 
Raztapljanje praška
• A vial water for injections containing 5 ml or 10 ml 
• vialo vode za injekcije, ki vsebuje 5 ml ali 10 ml
Nonafact may be self-administered if it is an approved practice in your country and when you have been trained sufficiently. 
Zdravilo Nonafact si lahko date sami, če je to dovoljeno v vaši državi in po ustreznem usposabljanju.
Frequency of doses (hours)/ Duration of therapy (days) 
Pogostnost odmerjanja (ure)/Trajanje zdravljenja (dnevi)
It is recommended that the rate of administration should not exceed 2 ml/min. 
Intravenska uporaba Priporočamo, da naj hitrost dajanja ne presega 2 ml/min.
In the case of a severe allergic reaction (anaphylactic shock), immediately stop the administration of the product and contact your doctor immediately. 
V primeru hude alergijske reakcije (anafilaktični šok), nemudoma prekinite dajanje zdravila in takoj pokličite svojega zdravnika.
In each of these situations, the benefit of treatment with Nonafact should be weighed against the risk of these complications. 
V vsaki od teh situacij moramo pretehtati korist zdravljenja z zdravilom Nonafact s tveganjem za te zaplete.
In some cases, these reactions have progressed to severe anaphylaxis, and they have occurred in close temporal association with development of factor IX inhibitors (see also 4.4). 
V nekaterih primerih so te reakcije napredovale v hudo anafilaksijo, pojavljale pa so se v tesni časovni povezavi z razvojem inhibitorjev faktorja IX (glejte tudi poglavje 4.4).
Known allergic reaction to mouse protein. 
Znana alergijska reakcija na mišje beljakovine.
This also applies to any unknown or emerging viruses or other types of infections. 
To velja tudi za doslej neznane ali na novo pojavljajoče se viruse ali druge oblike okužb.
Bring the two vials to a temperature between 15°C and 25°C. 
Ogrejte obe viali na temperaturo med 15 °C in 25 °C.
The administration of Nonafact can compensate for this deficiency. 
Uporaba zdravila Nonafact lahko nadomesti to pomanjkanje.
Your doctor will decide how much Nonafact you require. 
Vaš zdravnik bo odločil, koliko zdravila Nonafact potrebujete.
Nonafact contains sodium chloride 
Zdravilo Nonafact vsebuje natrijev klorid
There have been reports in the literature showing a correlation between the occurrence of a factor IX inhibitor and allergic reactions. 
V literaturi so poročali o korelaciji med pojavom inhibitorja faktorja IX in alergijskimi reakcijami.